Acute Lymphoblastic Leukemia Panel
ClonoSIGHT™ MRD test Submitted by Sequenta, Inc. on 10/15/2014
Ponatinib Submitted by ARIAD Pharmaceuticals Inc on 12/19/2016
Inotuzumab ozogamicin Submitted by Pfizer Inc. on 08/17/2017
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 08/31/2017
Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/15/2017
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 03/29/2018
Hypercvad rituximab Submitted by Oregon Society of Medical Oncology on 08/08/2018
clonoSEQ® Submitted by Adaptive Biotechnologies Corporation on 09/13/2018
Glucarpidase Submitted by BTG International Inc. on 09/24/2018
clonoSEQ® Submitted by Adaptive Biotechnologies Corporation on 09/28/2018
Dasatinib Submitted by Bristol-Myers Squibb Company on 01/03/2019
clonoSEQ Submitted by Adaptive Biotechnologies on 10/27/2020
Acute Myeloid Leukemia Panel
Isocitrate dehydrogenase (IDH) testing Submitted by Celgene Corporation on 07/14/2016
Midostaurin Submitted by Novartis Pharmaceuticals Corporation on 05/02/2017
Next-Generation Sequencing (NGS) Submitted by Illumina Inc. on 06/26/2017
Isocitrate dehydrogenase-2 (IDH-2) testing Submitted by Celgene Corporation on 08/02/2017
Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 08/07/2017
Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 09/08/2017
Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 10/03/2017
Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 10/12/2017
Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/15/2017
Gilteritinib Submitted by Astellas Pharma Inc. on 04/13/2018
Ivosidenib Submitted by Agios Pharmaceuticals, Inc on 04/23/2018
Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 04/27/2018
Cytarabine and Daunorubicin Submitted by Jazz Pharmaceuticals on 11/05/2018
Tagraxofusp Submitted by Stemline Therapeutics on 12/13/2018
Gilteritinib Submitted by Astellas Pharma Inc. on 01/18/2019
Liposomal Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 03/07/2019
Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 03/14/2019
Ivosidenib Submitted by Agios Pharmaceuticals, Inc on 04/02/2019
Gemtuzumab Ozogamicin Submitted by Pfizer Inc. on 04/22/2019
Tagraxofusp Submitted by Stemline Therapeutics, Inc. on 04/24/2019
Cytarabine and Daunorubicin Submitted by Jazz Pharmaceuticals on 04/26/2019
Gilterltinib Submitted by Astellas Pharma Inc. on 06/05/2019
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 05/01/2020
CC-486 Submitted by Bristol-Myers Squibb Company on 07/07/2020
Azacitidine Submitted by Bristol-Myers Squibb Company on 09/01/2020
Adult Cancer Pain Panel
Magnetic resonance-guided focused ultrasound Submitted by Insightec on 09/12/2016
Interventional radiology Submitted by Society of Interventional Oncology on 09/16/2019
Polymerized Cross-linked Sucralfate Submitted by MMI Script Hub and Medical Supplies on 06/18/2020
Algorithm & Discussion Changes Submitted by Society of Interventional Oncology on 08/11/2020
Antiemesis Panel
Granisetron Transdermal System Submitted by ProStrakan on 09/25/2014
Granisetron Injection Submitted by Heron Therapeutics, Inc. on 09/15/2015
Fosaprepitant Dimeglumine Submitted by Merck & Co., Inc. on 10/22/2015
Fosaprepitant Dimeglumine Submitted by Merck & Co., Inc. on 02/12/2016
Granisetron Submitted by Heron Therapeutics, Inc. on 08/10/2016
Fosaprepitant Dimeglumine Submitted by Merck & Co., Inc. on 10/17/2016
Carboplatin Submitted by Oncology Analytics, Inc. on 05/17/2017
Dronabinol Submitted by INSYS Therapeutics, Inc. on 08/11/2017
Granisetron Submitted by Heron Therapeutics, Inc. on 09/06/2017
Aprepitant Submitted by Heron Therapeutics, Inc. on 11/15/2017
Fosnetupitant and Palonosetron Submitted by Helsinn Healthcare SA on 05/18/2018
B-Cell Lymphomas Panel
Vitamin D-25OH and bone mineral density testing Submitted by Aurora Health Care on 04/07/2017
Rituximab and hyaluronidase Submitted by Genentech, Inc. on 06/23/2017
Copanlisib Submitted by Bayer Healthcare Pharmaceuticals on 09/15/2017
Copanlisib modification Submitted by Bayer Healthcare Pharmaceuticals on 10/18/2017
Copanlisib Submitted by Bayer Healthcare Pharmaceuticals on 10/18/2017
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 05/02/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 06/03/2018
Next-generation sequencing Submitted by Adaptive Biotechnologies on 07/18/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 08/07/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 12/03/2018
Obinutuzumab + Lenalidomide Submitted by Genentech, Inc. on 12/06/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 03/22/2019
Lenalidomide + Rituximab Submitted by Celgene Corporation on 05/28/2019
Polatuzumab vedotin Submitted by Genentech, Inc. on 06/10/2019
Obinutuzumab + Lenalidomide Submitted by Genentech, Inc. on 08/01/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 08/09/2019
Polatuzumab Vedotin Submitted by Genentech, Inc. on 12/17/2019
2 Gy x 2 fractions Submitted by Oncology Analytics, Inc. on 02/08/2020
Selinexor Submitted by Karyopharm Therapeutics on 06/23/2020
NGS clarification Submitted by Adaptive Biotechnologies Corporation on 09/01/2020
Siltuximab Submitted by Castleman Disease Collaborative Network (CDCN) on 09/08/2020
Lisocabtagene maraleucel Submitted by Bristol Myers Squibb on 02/08/2021
Bladder/Penile Cancers Panel
Radiation Therapy Submitted by American Society for Radiation Oncology on 09/10/2015
Radiation Therapy Submitted by American Society for Radiation Oncology on 09/10/2015
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/10/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 02/03/2017
Csbladder Assays Submitted by Pacific Edge Diagnostics USA, Ltd. on 07/31/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Molecular testing Submitted by Foundation Medicine, Inc. on 08/23/2018
Cxbladder Monitor Assay Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/31/2018
Erdafitinib Submitted by Janssen Scientific Affairs, LLC on 04/15/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/09/2019
Erdafitinib Submitted by Janssen Scientific Affairs, LLC on 07/30/2019
Genetic Alterations Submitted by Foundation Medicine, Inc. on 08/26/2019
Enfortumab vedotin Submitted by Seattle Genetics, Inc. on 12/06/2019
Avelumab Submitted by Pfizer Inc./EMD Serono, Inc. on 06/30/2020
Patient Advocate Recommendations Submitted by Bladder Cancer Advocacy Network (BCAN) on 07/27/2020
Urothelial tumor markers Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/13/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 08/28/2020
Avelumab Submitted by Pfizer Inc./EMD Serono, Inc. on 09/18/2020
Enfortumab vedotin Submitted by Seagen Inc./Astellas Pharma Global Development, Inc. on 02/16/2021
Bone Cancer Panel
Breast Cancer Panel
Zoledronic Acid Submitted by Novartis Pharmaceuticals Corporation on 05/09/2011
Everolimus Submitted by Novartis Pharmaceuticals Corporation on 10/10/2011
Ado-Trastuzumab Emtansine Submitted by Genentech on 02/22/2013
Toremifene Citrate Submitted by ProStrakan, Inc on 05/17/2013
Breast-Specific Gamma Imaging (BSGI) Submitted by Dilon Technologies on 06/27/2013
Breast Cancer Index (BCI) Submitted by bioTheranostics on 06/10/2014
CELLSEARCH Circulating Tumor Cell Test Submitted by Janssen Diagnostics on 06/20/2014
Prosigna Breast Cancer Gene Signature Assay Submitted by Nanostring Technologies on 06/20/2014
Oncotype DX Breast Cancer Assay Submitted by Genomic Health on 06/27/2014
HER-2 Blood Test Submitted by Nuclea Diagnostic Laboratories on 06/27/2014
Ado-Trastuzumab Emtansine Submitted by Genentech on 08/08/2014
Breast Cancer Index (BCI) Submitted by bioTheranostics, Inc. on 06/12/2015
Prosigna® Breast Cancer Gene Signature Assay Submitted by NanoString Technologies on 06/19/2015
Albumin-bound paclitaxel Submitted by Celgene Corporation on 04/28/2016
Preoperative HER2-targeted therapy Submitted by Genentech, Inc. on 05/09/2016
Albumin-bound paclitaxel Submitted by Celgene Corporation on 06/07/2016
Breast Cancer Index (BCI) test Submitted by Biotheranostics, Inc. on 06/14/2016
Prosigna® Breast Cancer Gene Signature Assay Submitted by NanoString Technologies on 06/14/2016
Oncotype DX® Invasive Breast Cancer Assay Submitted by Genomic Health Inc. on 06/17/2016
Oncotype DX® Breast Cancer Assay Submitted by Genomic Health Inc. on 06/17/2016
Biomarker assay Submitted by Myriad Genetic Laboratories, Inc. on 06/20/2016
Everolimus Submitted by Novartis Pharmaceuticals Corporation on 06/20/2016
Albumin-bound paclitaxel Submitted by Celgene Corporation on 01/13/2017
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 03/13/2017
70 gene MammaPrint assay Submitted by Agendia, Inc. on 05/26/2017
Pertuzumab/Trastuzumab Submitted by Genentech, Inc. on 06/12/2017
Prosigna® Breast Cancer Gene Signature Assay Submitted by NanoString Technologies on 06/23/2017
Docetaxel Submitted by Hadassah-Hebrew University Medical Center on 06/30/2017
70 gene MammaPrint assay Submitted by Agendia, Inc. on 07/03/2017
Bioimpedance spectroscopy Submitted by ImpediMed, Inc. on 07/10/2017
Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/10/2017
Oncotype DX® Breast Recurrence Score™ (RS) assay Submitted by Genomic Health, Inc. on 07/10/2017
Oncotype DX® Breast Recurrence Score™ (RS) assay Submitted by Genomic Health, Inc. on 07/10/2017
12-gene recurrence test Submitted by Myriad Genetic Laboratories, Inc. on 07/11/2017
Comprehensive genomic profiling (CGP) assays Submitted by Foundation Medicine, Inc. on 07/14/2017
Neratinib Submitted by Puma Biotechnology, Inc. on 07/17/2017
Everolimus Submitted by Novartis Pharmaceuticals Corporation on 07/19/2017
Abemaciclib Submitted by Eli Lilly and Company on 09/28/2017
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 12/06/2017
Neratinib Submitted by Puma Biotechnology, Inc. on 12/28/2017
Comprehensive genetic testing Submitted by Illumina Inc. on 02/08/2018
Abemaciclib Submitted by Eli Lilly and Company on 02/26/2018
Tamoxifen Submitted by Sanford Health Pharmacogenomics Committee on 02/28/2018
Paxman Scalp Cooling System Submitted by Paxman Coolers Limited on 06/12/2018
Ribociclib + Fulvestrant Submitted by AstraZeneca on 06/28/2018
Ribociclib + Fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 06/29/2018
Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Next-generation sequencing (NGS) Submitted by Foundation Medicine, Inc. on 07/03/2018
Radiofrequency spectroscopy Submitted by Dune Medical, Inc. on 07/05/2018
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2018
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2018
Ado-trastuzumab emtansine Submitted by Genentech, Inc. on 12/05/2018
Neratinib Submitted by Puma Biotechnology, Inc. on 12/21/2018
Genetic Testing Guidelines Submitted by Targeted Medical Education (TME) on 02/18/2019
Trastuzumab and Hyaluronidase-oysk Submitted by Genentech, Inc. on 02/28/2019
Alpelisib Submitted by Novartis Pharmaceuticals Corporation on 05/24/2019
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 05/28/2019
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 06/06/2019
Neratinib Submitted by Puma Biotechnology, Inc. on 06/10/2019
Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 06/10/2019
Locoregional therapies Submitted by Society of Interventional Oncology on 06/14/2019
Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/15/2019
Subclinical Lymphedema Submitted by Vanderbilt University School of Nursing on 07/19/2019
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
Genomic Assays Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
Trastuzumab-dttb Submitted by Samsung Bioepis Co., Ltd. on 07/24/2019
Atezolizumab, Pertuzumab, Ado-trastuzumab Emtansine Submitted by Genentech, Inc. on 07/24/2019
Next-Generation Sequencing Assays Submitted by Foundation Medicine, Inc. on 07/24/2019
Breast Cancer Index (BCI) Submitted by Biotheranostics, Inc. on 07/25/2019
Ixabepilone + Capecitabine Submitted by R-Pharm US on 07/30/2019
Abemaciclib Submitted by Eli Lilly and Company on 10/29/2019
EndoPredict Submitted by Myriad Genetics Laboratories Inc. on 01/27/2020
Estrogen receptor alpha-36 testing Submitted by Christina Rosati on 02/25/2020
Neratinib + capecitabine Submitted by Puma Biotechnology, Inc. on 02/27/2020
Sacituzumab govitecan-hziy Submitted by Immunomedics, Inc. on 04/22/2020
Alpelisib + fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 05/12/2020
TMB testing Submitted by Foundation Medicine, Inc. on 06/22/2020
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Submitted by Genentech, Inc. on 06/29/2020
Ado-trastuzumab emtansine Submitted by Linda W. Wilson, MD on 07/08/2020
Radiation Therapy Submitted by American Society for Radiation Oncology (ASTRO) on 07/20/2020
21-Gene RT-PCR assay Submitted by Exact Sciences on 07/28/2020
PET/CT Submitted by Society of Interventional Radiology on 07/30/2020
EndoPredict Submitted by Myriad Genetics Laboratories, Inc. on 08/01/2020
Pertuzumab + ado-trastuzumab emtansine Submitted by Genentech Inc. on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics Inc. on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics Inc. on 08/05/2020
NGS assay Submitted by Foundation Medicine Inc. on 08/06/2020
TMB testing Submitted by Foundation Medicine Inc. on 09/15/2020
Atezolizumab + albumin-bound paclitaxel Submitted by Genentech Inc. on 12/02/2020
Breast Cancer Risk Reduction Panel
Breast Cancer Screening and Diagnosis Panel
Cancer- and Chemotherapy-Induced Anemia Panel
Cancer in People with HIV/Kaposi Sarcoma Panel
Cancer-Associated Venous Thromboembolic Disease Panel
Central Nervous System Cancers Panel
Sunitinib Submitted by Pfizer Inc, Pfizer Oncology on 08/20/2014
NovoTTF<sup>TM</sup>-100A System Submitted by Novocure Inc. on 10/01/2014
NovoTTF<sup>TM</sup>-100A System Submitted by Accelerate Brain Cancer Cure on 11/24/2014
NovoTTF<sup>TM</sup>-100A System Submitted by National Brain Tumor Society on 11/25/2014
CNS brain metastatic lesions Submitted by Jiang Aijun and Zheng Xia on 08/23/2015
Tumor treating fields (TTFields) Submitted by Novocure Inc. on 11/06/2015
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/05/2017
Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/27/2017
Osimertinib Submitted by AstraZeneca Pharmaceuticals LP on 04/19/2018
Bevacizumab Submitted by Munson Medical Oncology on 05/02/2018
Glucarpidase Submitted by BTG International Inc. on 09/13/2018
Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 04/05/2019
Vitrakvi Submitted by Bayer Healthcare Pharmaceuticals on 05/28/2019
Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 06/10/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/18/2019
Cervical/Uterine Cancers Panel
Tamoxifen Submitted by Sarcoma Unit Royal Marsden Hospital, United Kingdom on 08/15/2012
Trabectedin Submitted by Janssen Biotech, Inc. on 10/23/2015
Olaratumab in combination with doxorubicin Submitted by Eli-Lilly and Company on 03/22/2017
Pembrolizumab for MSI-H/dMMR tumors for Cervical Cancer Submitted by Merck & Co. on 05/31/2017
Pembrolizumab for MSI-H/dMMR tumors for Uterine Neoplasms Submitted by Merck & Co. on 05/31/2017
Pembrolizumab for MSI-H/dMMR tumors for Vulvar Cancer Submitted by Merck & Co. on 05/31/2017
Radiation Therapy Submitted by American Society for Radiation Oncology on 04/30/2019
PCR-based Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 05/17/2019
Lenvatinib in combination with pembrolizumab Submitted by Eisai Inc. on 06/28/2019
Entrectinib and appropriate NTRK gene fusion testing Submitted by Genentech on 08/15/2019
Nivolumab for Vulvar Cancer Submitted by Bristol-Myers Squibb on 10/17/2019
Nivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb on 12/04/2019
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab dosing for Vulvar Cancer Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020
Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GSK on 05/15/2020
Pembrolizumab for Cervical Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab and TMB testing for Vulvar Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Chronic Myeloid Leukemia Panel
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 06/07/2010
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 06/17/2016
Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/17/2017
Dasatinib Submitted by Bristol-Myers Squibb Company on 12/10/2017
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 01/18/2018
Next-generation sequencing Submitted by Illumina Inc. on 02/27/2018
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 03/22/2018
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 03/22/2018
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 05/02/2019
CLL/SLL/Hairy Cell Leukemia Panel
Serum free light chain assays Submitted by Aurora Health Care on 04/07/2017
Rituximab/Hyaluronidase Submitted by Genentech, Inc. on 05/20/2017
Defibrotide sodium Submitted by Jazz Pharmaceuticals on 11/27/2017
TP53 genetic sequencing Submitted by Illumina Inc. on 04/06/2018
Moxetumomab pasudotox-tdfk Submitted by AstraZeneca on 09/15/2018
clonoSEQ assay Submitted by Adaptive Biotechnologies Corporation on 05/13/2019
Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 06/05/2019
Venetoclax + Rituximab Submitted by AbbVie Inc. on 06/05/2019
Rituximab-abbs Submitted by Teva Pharmaceuticals USA, Inc. on 09/23/2019
Acalabrutinib Submitted by AstraZeneca/Medical Affairs on 11/21/2019
Moxetumomab pasudotox-tdfk Submitted by Innate Pharma, Inc. on 05/08/2020
clonoSEQ Submitted by Adaptive Biotechnologies Corporation on 05/12/2020
Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 06/02/2020
Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 09/11/2020
Colon/Rectal/Anal Cancers Panel
Capecitabine (Colon Cancer) Submitted by Genentech on 06/07/2011
Capecitabine (Rectal Cancer) Submitted by Genentech on 06/07/2011
Fluoropyrimidine Pre-Screening Submitted by Ken Surprenant on 03/23/2014
Oncotype DX® Colon Cancer Assay Submitted by Genomic Health on 05/16/2014
PET/CT Submitted by Medical Imaging & Technology Alliance on 05/28/2014
PET/CT Submitted by Medical Imaging & Technology Alliance on 05/28/2014
Mitomycin C Submitted by Personalized Cancer Medicine on 02/23/2015
Trifluridine and Tipiracil Submitted by Taiho Oncology on 09/22/2015
Uridine Triacetate Submitted by Wellstat Therapeutics Corporation on 07/01/2016
Yttrium-90 resin microspheres Submitted by Sirtex Medical Inc. on 07/15/2016
Fluoropyrimidine Submitted by Kenneth E. Surprenant on 04/24/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 05/22/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 08/01/2017
Oncotype DX® Colon Recurrence Score® assay Submitted by Genomic Health, Inc. on 08/07/2017
CGP assays Submitted by Foundation Medicine, Inc. on 08/10/2017
Yttrium-90 Submitted by Sirtex Medical Limited on 08/16/2017
RAS molecular testing Submitted by Illumina Inc. on 01/03/2018
RAS molecular testing Submitted by Illumina Inc. on 01/03/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 01/22/2018
Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 01/26/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Trastuzumab + Pertuzumab Submitted by Genentech, Inc. on 05/11/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/11/2018
Radiation Therapy Submitted by American Society for Radiation Oncology (ASTRO) on 07/31/2018
Fluoropyrimidines Submitted by Gabriel A. Brooks, MD, MPH & Ken Surprenant on 08/08/2018
Comprehensive Genomic Profiling (CGP) assay Submitted by Foundation Medicine, Inc. on 08/09/2018
Vitrakvi Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Encorafenib + Binimetinib + Cetuximab Submitted by Array BioPharma Inc. on 02/26/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/19/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 05/03/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/03/2019
Transanal full thickness local excision Submitted by Ascension St. John Hospital on 06/04/2019
Encorafenib + Binimetinib + Cetuximab Submitted by Array BioPharma Inc. on 07/16/2019
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 07/24/2019
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 07/24/2019
Levoleucovorin Submitted by Acrotech Biopharma LLC on 07/25/2019
DPYD genetic testing Submitted by University of Michigan College of Pharmacy on 07/29/2019
Regorafenib + Nivolumab Submitted by Bayer Healthcare Pharmaceuticals on 07/30/2019
yttrium-90 Submitted by Society of Interventional Oncology on 08/08/2019
Comprehensive genomic profiling (CGP) Submitted by Guardant Health, Inc. on 01/30/2020
Pembrolizumab for Anal Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 06/01/2020
Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 06/10/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Post-surgical tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Post-surgical tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
yttrium-90 Submitted by Society of Interventional Oncology on 07/14/2020
Next-generation sequencing (NGS) Submitted by Guardant Health, Inc. on 07/20/2020
Circulating Tumor DNA (ctDNA) Submitted by Colorectal Cancer Alliance on 08/10/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Colorectal Cancer Screening Panel
Distress Management Panel
Esophageal/Gastric Cancers Panel
Uridine triacetate Submitted by Wellstat Therapeutics Corporation on 08/17/2016
High‐Risk Syndromes Submitted by Myriad Genetic Laboratories, Inc. on 08/17/2016
Pembrolizumab for Gastric Cancer Submitted by Merck & Co. on 05/31/2017
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co. on 05/31/2017
Nivolumab for Gastric Cancer Submitted by Bristol-Myers Squibb on 09/21/2017
Nivolumab for Esophageal and Esophagogastric Cancer Submitted by Bristol-Myers Squibb on 09/21/2017
Pembrolizumab for PD-L1 tumors for Gastric Cancer Submitted by Merck & Co. on 09/29/2017
Trifluridine/Tipiracil Submitted by Taiho Oncology, Inc. on 07/13/2018
Trastuzumab Submitted by Eli Lilly and Company on 07/17/2018
Principles of Pathologic Review Submitted by Foundation Medicine, Inc. on 09/11/2018
Scalp cooling system for Esophageal and Gastric Submitted by Paxman Coolers Limited on 07/26/2019
Trastuzumab-dttb Submitted by Samsung Bioepis Co., Ltd on 08/02/2019
Entrectinib and appropriate NTRK gene fusion testing Submitted by Genentech, Inc. on 08/15/2019
Comprehensive genetic profiling Submitted by Foundation Medicine, Inc. on 09/05/2019
Nivolumab for Esophageal Cancer Submitted by Bristol-Myers Squibb on 09/30/2019
Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc. on 03/12/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Esophageal and Esophagogastric Cancer Submitted by Merck & Co., Inc on 04/29/2020
Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc on 04/29/2020
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 06/04/2020
Nivolumab for Esophageal squamous cell carcinoma Submitted by Bristol Myers Squibb on 06/11/2020
Pembrolizumab for TMB-H for Esophageal Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for TMB for Gastric Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/26/2020
Pembrolizumab with chemotherapy for Esophageal Cancer Submitted by Merck & Co., Inc. on 09/21/2020
Nivolumab for Esophageal Cancer Submitted by Bristol Myers Squibb, Inc. on 09/23/2020
Nivolumab for Gastric Cancer Submitted by Bristol Myers Squibb, Inc. on 09/23/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 11/04/2020
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel
Multigene Panel Testing Submitted by Myriad Genetic Laboratories, Inc. on 05/14/2016
Personal History of Pancreatic Cancer Submitted by Myriad Genetic Laboratories, Inc. on 05/14/2016
PALB2 Submitted by Myriad Genetic Laboratories, Inc. on 04/11/2017
BRCA testing Submitted by Myriad Genetic Laboratories, Inc. on 04/17/2017
Multigene Panel Testing Submitted by Myriad Genetic Laboratories, Inc. on 04/17/2017
Genetic risk evaluation Submitted by Baltimore Suburban Health on 08/03/2017
Next-generation sequencing Submitted by Illumina Inc. on 10/18/2017
Further Risk Evaluation Submitted by Myriad Genetic Laboratories, Inc. on 03/09/2018
HBOC‐related cancer Submitted by Myriad Genetic Laboratories, Inc. on 03/09/2018
RAD51D gene variations Submitted by Hines & Associates, Inc on 02/28/2019
Genetic Testing Submitted by Myriad Genetics, Inc. on 04/01/2019
Prostate Cancer Testing Criteria Submitted by Myriad Genetics, Inc. on 04/02/2019
PALB2 testing criteria Submitted by Myriad Genetics, Inc. on 04/03/2019
Personal history of ovarian carcinoma Submitted by Myriad Genetics, Inc. on 04/03/2019
Genetic Testing Submitted by University of Minnesota Medical Center on 05/31/2019
BARD1- and RAD51D-associated breast cancer risk Submitted by Ambry Genetics on 10/03/2019
Multi-gene testing Submitted by Ambry Genetics on 10/03/2019
High Penetrance Genes Submitted by Myriad Genetic Laboratories, Inc. on 03/25/2020
Prostate Cancer Testing Criteria Submitted by Myriad Genetic Laboratories, Inc. on 04/01/2020
Genetic/Familial High-Risk Assessment: Colorectal Panel
Genetic: Colorectal/Colorectal Cancer Screening Panel
Genetic risk assessment Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016
LS-specific testing Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016
Multi-gene testing Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016
MSI‐H histology Submitted by Myriad Genetic Laboratories, Inc. on 10/01/2017
Head and Neck Cancers Panel
Fluoropyrimidine Pre-Screening Submitted by Ken Surprenant on 04/06/2014
Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc on 06/10/2015
Nivolumab Submitted by Bristol Myers Squibb Company on 04/19/2016
Nivolumab Submitted by Bristol Myers Squibb Company on 06/06/2016
Technetium Tc 99m tilmanocept Submitted by Navidea Biopharmaceuticals on 07/18/2016
Hybrid capture based NGS Submitted by Foundation Medicine, Inc. on 08/22/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/13/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2018
Larotrectinib Submitted by Bayer HealthCare Pharmaceuticals on 10/15/2018
NCCN Evidence Blocks Submitted by Merck & Co., Inc. on 06/18/2020
Hematopoietic Cell Transplantation Panel
Hematopoietic Growth Factors Panel
Pegfilrastim delivery kit/on-body injector Submitted by Amgen, Inc. on 05/13/2015
Plerixafor dosing and references Submitted by Sanofi U.S. on 12/14/2015
Febrile neutropenia risk of CHOP/R-CHOP Submitted by Amgen Inc. on 05/22/2017
MGF in the palliative setting Submitted by William Stephenson, MD on 07/21/2017
5-flurorouracil, oxaliplatin, leucovorin Submitted by Oncology Analytics, Inc. on 02/05/2019
Pegfilgrastim-cbqv Submitted by Coherus BioSciences on 02/11/2019
Hepatobiliary Cancers Panel
Nivolumab Submitted by Bristol-Myers Squibb Company on 09/26/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Ramucirumab Submitted by Eli Lilly and Company on 06/22/2018
Molecular testing Submitted by Foundation Medicine, Inc. on 08/23/2018
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 10/30/2018
Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 12/19/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 01/18/2019
Ramucirumab Submitted by Eli Lilly and Company on 05/16/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/11/2019
Molecular Testing Submitted by Bayer HealthCare on 08/23/2019
Locoregional therapy Submitted by Society of Interventional Oncology on 08/26/2019
Cholangiocarcinoma Submitted by Foundation Medicine, Inc. on 09/24/2019
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 09/27/2019
Cholangiocarcinoma Submitted by Foundation Medicine, Inc. on 10/01/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/02/2019
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 11/23/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 03/11/2020
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/13/2020
Molecular testing Submitted by Foundation Medicine, Inc. on 05/14/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Radioembolization Submitted by Society of Interventional Oncology on 10/01/2020
Pralsetinib Submitted by Blueprint Medicines Corporation on 10/02/2020
Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 10/08/2020
Hodgkin Lymphoma Panel
Brentuximab vedotin Submitted by Seattle Genetics on 09/05/2014
Brentuximab vedotin Submitted by Seattle Genetics on 09/05/2014
Panobinostat Submitted by Novartis Pharmaceuticals Organization on 02/24/2015
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/25/2015
Vitamin D-25OH and bone mineral density testing Submitted by Aurora Health Care on 04/07/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/25/2017
Brentuximab vedotin Submitted by Seattle Genetics on 05/05/2017
Brentuximab vedotin + AVD Submitted by Seattle Genetics Inc. on 12/10/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/20/2018
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 04/15/2019
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/26/2019
Kidney Cancer Panel
Radiation Therapy Submitted by American Society for Radiation Oncology on 05/24/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/16/2018
Pazopanib Submitted by Novartis Pharmaceuticals Corporation on 05/29/2018
Avelumab + Axitinib Submitted by EMD Serono, Inc. on 02/20/2019
T1a renal masses Submitted by Society of Interventional Oncology on 03/15/2019
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020
Thermal Ablation Submitted by Society of Interventional Oncology on 03/02/2020
Nivolumab + Cabozantinib Submitted by Bristol Myers Squibb on 01/25/2021
Nivolumab + Cabozantinib Submitted by Exelixis, Inc. on 01/25/2021
Lenvatinib + pembrolizumab Submitted by Eisai Inc. on 02/13/2021
Kidney/Testicular Cancers Panel
Lung Cancer Screening Panel
Management of Immunotherapy-Related Toxicity Panel
Melanoma Panel
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/22/2014
Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/15/2015
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 05/20/2015
Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/01/2015
Talimogene laherparepvec Submitted by Amgen Inc. on 10/28/2015
Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/29/2015
Cobimetinib/vemurafenib Submitted by Genentech, Inc. on 11/10/2015
Nivolumab Submitted by Bristol-Myers Squibb Company on 11/30/2015
Decision Dx-Melanoma test Submitted by Castle Biosciences, Inc. on 06/24/2016
Counseling and genetic testing Submitted by Oregon Health and Science University on 06/27/2016
Genetic risk assessment/testing Submitted by Myriad Genetic Laboratories, Inc. on 06/29/2016
Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/09/2016
Nivolumab/ipilimumab Submitted by Bristol-Myers Squibb Company on 04/04/2017
Pembrolizumab for MSI-H/dMMR tumors Submitted by Merck & Co. on 05/31/2017
DecisionDx-Melanoma test Submitted by Castle Biosciences Incorporated on 06/01/2017
Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/05/2017
CDx assay Submitted by Foundation Medicine, Inc. on 06/07/2017
Talimogene Laherparepvec in combination with ipilimumab Submitted by Amgen Inc. on 06/29/2017
Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/11/2017
Talimogene laherparepvec Submitted by Amgen, Inc. on 10/16/2017
Talimogene laherparepvec/ipilimumab Submitted by Amgen on 02/28/2018
Talimogene laherparepvec/pembrolizumab Submitted by Amgen on 02/28/2018
Next-generation based testing Submitted by Illumina Inc. on 05/18/2018
Adhesive patch based non-invasive skin sampling tool Submitted by DermTech on 05/31/2018
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Pigmented Lesion Assay (PLA) Submitted by DermTech on 06/27/2019
DecisionDx-Melanoma Test Submitted by Castle Biosciences, Incorporated on 06/28/2019
Pembrolizumab dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020
Pembrolizumab dosing Submitted by Merck & Co., Inc. on 04/29/2020
Footnote and gene mutation listings Submitted by Myriad Genetic Laboratories, Inc. on 06/09/2020
Pembrolizumab weight-based dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
GEP using DecisionDx-UM for Uveal Melanoma Submitted by Castle Biosciences on 06/15/2020
Pigmented lesion assay (PLA) Submitted by DermTech, Inc. on 06/16/2020
DecisionDx-Melanoma test (31-GEP) Submitted by Castle Biosciences on 06/17/2020
PLA Submitted by Dermatologic Surgery Center of Washington, LLC on 06/21/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 06/22/2020
Gene expression profiling (GEP) Submitted by Myriad Genetic Laboratories, Inc. on 06/22/2020
PLA Submitted by University of Pittsburgh School of Medicine Department of Dermatology on 06/23/2020
Pembrolizumab and low-dose ipilimumab for first-line Submitted by Merck & Co., Inc. on 07/21/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 09/15/2020
Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel
Daratumumab Submitted by Janssen Biotech, Inc. on 11/23/2015
Elotuzumab Submitted by Bristol-Myers Squibb Company on 11/30/2015
Bendamustine Hydrochloride Submitted by Teva Pharmaceuticals, Inc. on 03/23/2016
Panobinostat Submitted by Novartis Pharmaceuticals Corporation on 04/11/2016
Carfilzomib Submitted by The University of Chicago, Department of Medicine on 04/11/2016
Elotuzumab Submitted by Bristol-Myers Squibb Company on 04/21/2016
Daratumumab Submitted by Janssen Biotech, Inc. on 06/07/2016
Daratumumab Submitted by Janssen Biotech, Inc. on 10/21/2016
Carfilzomib in combination with lenalidomide and dexamethasone Submitted by Amgen Inc. on 01/26/2017
Pomalidomide + Dexamethasone Submitted by Celgene Corporation on 03/30/2018
Ixazomib Maintenance Submitted by Takeda Oncology on 04/23/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 05/09/2018
Minimal Residual Disease (MRD) analysis Submitted by Adaptive Biotechnologies on 05/10/2018
Daratumumab + Carfilzomib + Dexamethasone Submitted by Janssen Biotech, Inc. on 06/07/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 12/06/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 02/12/2019
clonoSEQ® assay Submitted by Adaptive Biotechnologies Corporation on 04/26/2019
SKY92 high risk gene expression signature Submitted by SkylineDx on 04/30/2019
SKY92 high risk gene expression signature Submitted by SkylineDx on 04/30/2019
Daratumumab Submitted by Janssen Biotech, Inc. on 05/09/2019
Daratumumab Submitted by Janssen Biotech, Inc. on 06/07/2019
Selinexor Submitted by Karyopharm Therapeutics on 07/22/2019
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 09/27/2019
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 12/20/2019
Lenalidomide Submitted by Bristol-Myers Squibb Company on 01/16/2020
Dexamethasone Submitted by Acrotech Biopharma, LLC on 03/18/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies Corporation on 03/27/2020
Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020
Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 05/12/2020
Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 08/05/2020
Selinexor Submitted by Karyopharm Therapeutics on 11/12/2020
Melphalan flufenamide Submitted by Oncopeptides, Inc. on 03/01/2021
Myelodysplastic Syndromes Panel
Next-generation sequencing Submitted by Illumina Inc. on 11/30/2017
Patient evaluation Submitted by Foundation Medicine, Inc. on 03/26/2018
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 01/09/2020
Luspatercept-aamt Submitted by Bristol Myers Squibb on 04/10/2020
Decitabine and Cedazuridine Submitted by Taiho Oncology, Inc. on 07/10/2020
Myeloproliferative Neoplasms Panel
Neuroendocrine Tumors Panel
Everolimus Submitted by Novartis Pharmaceuticals Corporation on 09/08/2010
Lanreotide Submitted by Ipsen Biopharmaceuticals, Inc. on 11/14/2012
Lanreotide Submitted by Ipsen Biopharmaceuticals, Inc. on 06/23/2014
Gallium-68 Dotatate PET/CT Submitted by Medical Imaging and Technology Alliance on 06/15/2016
Telotristat ethyl Submitted by Lexicon Pharmaceuticals, Inc. on 03/09/2017
Everolimus + Octreotide (LAR) Submitted by Novartis Pharmaceutical Corporation on 07/07/2017
HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals, Inc. on 07/10/2018
HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 09/07/2018
HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 09/11/2018
Telotristat ethyl Submitted by Lexicon Pharmaceuticals, Inc. on 05/06/2019
Liver-Directed Therapy Submitted by Society of Interventional Oncology on 10/15/2019
Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2020
Non-Hodgkin`s Lymphomas Panel
Ibritumomab Submitted by Spectrum Pharmaceuticals, Inc. on 05/12/2010
Brentuximab Vedotin Submitted by Seattle Genetics on 08/19/2011
Brentuximab vedotin Submitted by Seattle Genetics on 06/20/2013
Brentuximab vedotin (DLBCL) Submitted by Seattle Genetics on 05/28/2014
Brentuximab vedotin (CTCL) Submitted by Seattle Genetics on 05/28/2014
Ibritumomab tiuxetan Submitted by Spectrum Pharmaceuticals on 06/02/2014
Ibrutinib (CLL- elderly) Submitted by Pharmacyclics on 06/11/2014
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 05/26/2016
Ofatumumab Submitted by Novartis Pharmaceuticals Corporation on 06/03/2016
Ibrutinib + Rituximab Submitted by Pharmacyclics on 12/07/2016
Non-Melanoma Skin Cancer Panel
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 06/15/2018
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/28/2019
Pembrolizumab for Basal Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Merkel Cell Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 03/26/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 06/25/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 07/08/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/14/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/10/2021
Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas Panel
Albumin-bound Paclitaxel with Carboplatin Submitted by Celgene on 06/25/2012
FDG PET/CT Submitted by Medical Imaging & Technology Alliance on 06/01/2014
Vemurafenib, Dabrafenib, Cabozantinib Submitted by Oncology Analytics on 10/06/2014
Vemurafenib, Dabrafenib, Crizotinib Submitted by Oncology Analytics on 02/18/2015
Afatinib with Cetuximab Submitted by Boehringer Ingelheim on 03/23/2015
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2015
Necitumumab Submitted by Eli Lilly and Company on 11/25/2015
Ramucirumab Submitted by Eli Lilly and Company on 11/30/2015
Necitumumab Submitted by Eli Lilly and Company on 03/25/2016
Nivolumab, Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2016
Molecular Prognostic Score Submitted by Myriad Genetic Laboratories, Inc. on 06/08/2016
Tyrosine Kinase Inhibitors Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 06/15/2016
Test Results Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 06/16/2016
Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 06/17/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/28/2016
Dabrafenib and Trametinib Submitted by Novartis Pharmaceuticals Corporation on 08/29/2016
Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 12/05/2016
Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 03/08/2017
Molecular profiling Submitted by Foundation Medicine, Inc. on 05/26/2017
Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 06/01/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2017
Ramucirumab Submitted by Eli Lilly and Company on 11/20/2017
Guardant360 Submitted by Guardant Health, Inc. on 12/06/2017
Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 01/23/2018
Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 03/06/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Next-generation sequencing Submitted by Illumina Inc. on 04/11/2018
Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2018
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/04/2018
Tumor Mutational Burden Submitted by Foundation Medicine, Inc. on 05/25/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/03/2018
Atezolizumab and Alectinib Submitted by Genentech, Inc. on 06/04/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2018
Dabrafenib and Trametinib Submitted by Novartis Pharmaceuticals Corporation on 06/15/2018
Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 07/24/2018
Guardant360 Submitted by Guardant Health, Inc. on 09/23/2018
Guardant360 Submitted by Guardant Health, Inc., on 09/23/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 09/27/2018
Afatinib Addendum Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 10/11/2018
Durvalumab Submitted by AstraZeneca Pharmaceuticals LP/Medical Affairs on 10/25/2018
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 02/13/2019
Brigatinib Post Crizotinib Submitted by Takeda Oncology on 06/10/2019
Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 06/21/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/28/2019
Ramucirumab Submitted by Eli Lilly and Company on 10/29/2019
Guardant360 Submitted by Guardant Health, Inc. on 01/22/2020
Selpercatinib Submitted by Eli Lilly and Company on 03/27/2020
Guardant360 Submitted by Guardant Health, Inc. on 03/27/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 05/06/2020
Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/15/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 05/26/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 05/29/2020
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Key Recommendations Submitted by American Society for Radiation Oncology on 06/23/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 06/30/2020
Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 07/01/2020
Guardant360 Submitted by Guardant Health, Inc. on 07/02/2020
Tumor Treating Fields Submitted by Novocure Inc. on 07/03/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 07/08/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 08/08/2020
Pralsetinib Submitted by Blueprint Medicines Corporation on 09/08/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 10/02/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 11/04/2020
Durvalumab Submitted by AstraZeneca Pharmaceuticals LP on 11/20/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 01/18/2021
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 01/21/2021
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/16/2021
Occult Primary Panel
Older Adult Oncology Panel
Ovarian Cancer Panel
BRCA test Submitted by Ovarian Cancer National Alliance on 10/15/2015
Genetic testing for BRCA status Submitted by Myriad Genetics Laboratories, Inc. on 10/23/2015
Trabectedin/docetaxel Submitted by Janssen Biotech on 09/30/2016
Multivariate index assay test OVA1 Submitted by Vermillion/ASPiRA Labs on 10/18/2016
Next-generation sequencing (NGS) Submitted by Illumina Inc. on 10/09/2017
Avelumab Submitted by EMD Serono, Inc. and Pfizer Inc. on 10/20/2017
OVA1/Multivariate Index Assay Submitted by Vermillion/AsPIRA Laboratories on 10/24/2017
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 10/25/2017
PARP inhibitor maintenance Submitted by Tesaro Inc. on 10/10/2018
Paxman Scalp Cooling System Submitted by Paxman Coolers Limited on 07/26/2019
OVA1/Multivariate Index Assay Submitted by Vermillion, Inc. on 09/18/2019
Bevacizumab-awwb Submitted by Tejas Patel, PharmD, BCOP United Healthcare on 09/26/2019
Molecular testing Submitted by Foundation Medicine, Inc. on 10/02/2019
Trabectedin Submitted by Janssen Scientific Affairs on 02/04/2020
myChoice CDx Submitted by Myriad Genetics Laboratories on 09/08/2020
OVA1 Multivariate Index Assay Submitted by ASPiRA Women’s Health on 09/10/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals on 09/16/2020
CDx genomic profiling test Submitted by Foundation Medicine, Inc. on 11/06/2020
Palliative Care Panel
Pancreatic Adenocarcinoma Panel
Albumin-bound paclitaxel Submitted by Celgene Corporation on 08/21/2015
Familial/genetic risk assessment Submitted by Myriad Genetics Laboratories, Inc. on 08/21/2015
Irinotecan liposome injection Submitted by Merrimack Pharmaceuticals on 04/11/2016
Irreversible electroporation Submitted by AngioDynamics on 08/10/2016
Genetic testing Submitted by Myriad Genetic Laboratories, Inc. on 08/11/2016
Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 07/03/2018
Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 06/25/2019
Evidence Blocks Submitted by United Healthcare on 02/24/2020
Germline testing Submitted by Myriad Genetics Laboratories, Inc. on 06/08/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 06/12/2020
Gemcitabine/albumin-bound paclitaxel/cisplatin Submitted by Dr. Dan Laheru on 06/18/2020
Pediatric Acute Lymphoblastic Leukemia Panel
Pediatric Hodgkin Lymphoma Panel
Prevention and Treatment of Cancer-Related Infections Panel
Fidaxomicin Submitted by Cubist Pharmaceuticals on 09/11/2014
Isavuconazonium sulfate Submitted by Astellas Pharma Global Development, Inc on 08/31/2016
Oritavancin Submitted by Global Health Science on 09/30/2016
Meropenem and Vaborbactam Submitted by Melinta Therapeutics, Inc. on 10/01/2018
Temp Traq Submitted by Blue Spark Technologies on 06/26/2019
Prostate Cancer Early Detection Panel
Family History Submitted by Myriad Genetic Laboratories, Inc. on 09/19/2016
3-gene expression assay Submitted by Exosome Diagnostics, Inc. on 01/04/2017
Family History Submitted by Myriad Genetic Laboratories, Inc. on 08/02/2017
3-gene expression assay Submitted by Exosome Diagnostics, Inc on 01/05/2018
EPI biomarker Submitted by Exosome Diagnostics, Inc on 04/23/2018
3-gene expression assay Submitted by Exosome Diagnostics, Inc on 08/13/2018
EPI test Submitted by Exosome Diagnostics, Inc on 09/20/2018
Germline Genetic Testing Submitted by Myriad Genetic Laboratories, Inc. on 09/18/2020
miR Scientific Sentinel™ Prostate Cancer Test Platform Submitted by miR Scientific on 09/29/2020
Prostate Cancer Panel
Sipuleucel-T Submitted by Dendreon Corporation on 05/03/2010
Abiraterone Acetate Submitted by Centocor Ortho Biotech on 04/28/2011
Sipuleucel-T Submitted by Dendreon Corporation on 07/25/2011
Degarelix Submitted by Ferring Pharmaceuticals on 08/22/2011
Degarelix Submitted by Ferring Pharmaceuticals on 11/01/2011
Abiraterone Acetate Submitted by Janssen Biotech on 12/10/2012
Radium Ra 223 Dichloride Submitted by Bayer Healthcare Pharmaceuticals on 05/16/2013
Docetaxel in combination with androgen deprivation therapy (ADT) Submitted by Sanofi on 06/03/2014
Cellsearch Submitted by Janssen Diagnostics, LLC on 04/24/2015
ProMark Submitted by Johns Hopkins Medical Insitutions on 05/01/2015
Decipher® Prostate Cancer Classifier Submitted by GenomeDx Biosciences Inc. on 05/12/2015
Oncotype DX Prostate Cancer Assay Submitted by Genomic Health Inc. on 05/29/2015
Genetic risk assessment/testing Submitted by Myriad Genetic Laboratories, Inc. on 05/27/2016
PET/CT Imaging Submitted by Medical Imaging & Technology Alliance on 05/27/2016
PET Imaging Submitted by Blue Earth Diagnostics, Inc. on 05/27/2016
PTEN status Submitted by Eastern Virginia Medical School on 06/09/2016
Uridine triacetate Submitted by Wellstat Therapeutics on 08/16/2016
Tissue-based molecular assay Submitted by GenomeDx Biosciences Inc. on 06/01/2017
Tumor-based molecular assays Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2017
Abiraterone acetate Submitted by Janssen Scientific Affairs, LLC on 06/08/2017
Abiraterone Acetate Submitted by Kansas City Urology Care on 12/07/2017
Apalutamide Submitted by Janssen Scientific Affairs, LLC on 02/15/2018
Enzalutamide Submitted by Astellas Pharma Inc. on 03/15/2018
Apalutamide Submitted by Janssen Scientific Affairs, LLC on 05/23/2018
Genomic classifier Submitted by GenomeDx Biosciences Inc. on 06/01/2018
Fluciclovine Submitted by Blue Earth Diagnostics, Inc. on 06/06/2018
Prolaris Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2018
Prolaris Post‐RP Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2018
Denosumab and Zolendronic Acid Submitted by Prostate Health Education Network, Inc. on 06/20/2018
GnRH antagonist degarelix Submitted by Ferring Pharmaceuticals on 10/11/2018
Abiraterone Acetate Submitted by Value in Cancer Care Consortium (ViC3) on 10/14/2018
Sipuleucel-T Submitted by Dendreon Pharmaceuticals LLC on 02/19/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 03/15/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 04/09/2019
Tumor Tissue-Based Molecular Assay Submitted by Decipher Biosciences Inc. on 06/01/2019
Apalutamide Submitted by Janssen Scientific Affairs, LLC on 06/04/2019
Genetic Testing in Active Surveillance Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019
Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019
PCR-based Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 06/06/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 06/11/2019
Enzalutamide Submitted by Astellas Pharma Global Development, Inc. on 07/29/2019
Guardant360 Submitted by Guardant Health, Inc. on 04/22/2020
Molecular/Biomarker Analysis Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020
Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 04/29/2020
Darolutamide Submitted by Bayer Healthcare Pharmaceuticals on 05/11/2020
Small Cell Lung Cancer Panel
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/11/2019
Durvalumab Submitted by AstraZeneca Pharmaceuticals on 09/19/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/04/2019
Lurbinectedin Submitted by Jazz Pharmaceuticals on 04/29/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals on 06/15/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/29/2020
Smoking Cessation Panel
Soft Tissue Sarcoma Panel
Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 10/03/2012
Diagnostic Algortihm Submitted by The Life Raft Group on 05/21/2019
ENLIVEN, pexidartinib Submitted by Daiichi-Sankyo on 08/05/2019
Avapritinib Submitted by Blueprint Medicines Corporation on 01/07/2020
Avapritinib Submitted by Blueprint Medicines Corporation on 01/09/2020
Treatment Algorithm Submitted by The Desmoid Tumor Research Foundation on 03/17/2020
Ripretinib Submitted by Deciphera Pharmaceuticals on 05/18/2020
Footnotes Submitted by Society of Interventional Oncology on 06/08/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 06/17/2020
Ripretinib Submitted by Deciphera Pharmaceuticals on 06/19/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/23/2020
Ripretinib Submitted by Deciphera Pharmaceuticals on 08/17/2020
Survivorship Panel
Genetic risk assessment/testing Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2015
Bioimpedance spectroscopy (L-Dex U400) Submitted by ImpediMed, Inc. on 10/28/2015
Genetic risk assessment Submitted by Myriad Genetic Laboratories, Inc. on 10/10/2016
Naloxegol Submitted by AstraZeneca/Medical Affairs on 10/04/2017
Lymphedema symptom assessment Submitted by Vanderbilt University School of Nursing on 10/31/2018
Genetic risk assessment and testing Submitted by Myriad Genetic Laboratories on 10/29/2019
T-Cell/Primary Cutaneous Lymphomas Panel
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 05/30/2017
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/07/2017
Next-generation sequencing (NGS) Submitted by Illumina Inc. on 05/07/2018
Next generation sequence based analysis Submitted by Adaptive Biotechnologies on 05/18/2018
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 11/21/2018
Duvelisib + Romidepsin Submitted by Verastem, Inc. on 05/17/2019
Next-generation sequencing (NGS) Submitted by Adaptive Biotechnologies Corporation on 06/28/2019
Leucovorin Submitted by Acrotech Biopharma, LLC on 06/12/2020
ENKTL Submitted by Sun Yat-sen University Cancer Center on 06/14/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies Corporation on 06/19/2020
Testicular Cancer Panel
Thyroid Carcinoma Panel
Sorafenib Submitted by Bayer HealthCare Pharmaceuticals and Onxy Pharmaceuticals, Inc. on 06/26/2013
Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 01/09/2018
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 10/15/2018
Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/29/2020
Pralsetinib Submitted by Blueprint Medicines Corporation on 12/01/2020